Disclosures for "A Phase 1, Open-label, Single Center Study of KYV-101, an Autologous Fully-human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis"
-
Dr. Dunn has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Dunn has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. The institution of Dr. Dunn has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Progentec Diagnostics. Dr. Dunn has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyverna Therapeutics. Dr. Dunn has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Galetta has received personal compensation in the range of $0-$499 for serving as a Speaker with AAN.
-
Miss Tomczak has nothing to disclose.
-
Dr. Timmons has nothing to disclose.
-
Crystal Ton-Nu has nothing to disclose.
-
Miss Sumera has nothing to disclose.
-
Emma A. Martinez has nothing to disclose.
-
Dr. lowsky has nothing to disclose.